FIRST AMENDMENT TO THE CD71 CO-DEVELOPMENT AND LICENSE AGREEMENTCd71 Co-Development and License Agreement • November 6th, 2018 • CytomX Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment (the “Amendment”) to the CD7l Co-Development and License Agreement dated April 21, 2016 (the “Agreement”) by and between CytomX Therapeutics, Inc., a corporation organized under the laws of Delaware (“Licensor”) and AbbVie Ireland Unlimited Company, an unlimited company organized under the laws of Ireland (“AbbVie”) is effective as of October 5, 2016. Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
THIRD AMENDMENT TO THE CD71 CO-DEVELOPMENT AND LICENSE AGREEMENTCd71 Co-Development and License Agreement • November 6th, 2018 • CytomX Therapeutics, Inc. • Pharmaceutical preparations
This Third Amendment (the “Amendment”) to the CD71 Co-Development and License Agreement dated April 21, 2016, as amended (the “Agreement”) by and between CytomX Therapeutics, Inc., a corporation organized under the laws of Delaware (“Licensor”) and AbbVie Ireland Unlimited Company, an unlimited company organized under the laws of Ireland (“AbbVie” ) is effective as of January 3, 2018. Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SECOND AMENDMENT TO THE CD71 CO-DEVELOPMENT AND LICENSE AGREEMENTCd71 Co-Development and License Agreement • November 6th, 2018 • CytomX Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment (the “Amendment”) to the CD71 Co-Development and License Agreement dated April 21, 2016, as amended (the “Agreement”) by and between CytomX Therapeutics, Inc., a corporation organized under the laws of Delaware (“Licensor”) and AbbVie Ireland Unlimited Company, an unlimited company organized under the laws of Ireland (“AbbVie”) is effective as of March 31, 2017. Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
